RGNX Quote, Financials, Valuation and Earnings

PTC Therapeutics has a net margin of 6.83% compared to Regenxbio's net margin of 73.68%. Regenxbio's return on equity of -50.09% beat PTC Therapeutics's return on equity of --.

Regenxbio has a consensus price target of $32.00, signalling upside risk potential of 229.56%. On the other hand PTC Therapeutics has an analysts' consensus of $61.13 which suggests that it could grow by 33.1%. Given that Regenxbio has higher upside potential than PTC Therapeutics, analysts believe Regenxbio is more attractive than PTC Therapeutics.

Regenxbio has a beta of 1.115, which suggesting that the stock is 11.488% more volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.522, suggesting its less volatile than the S&P 500 by 47.837%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than PTC Therapeutics quarterly revenues of $1.2B. Regenxbio's net income of $6.1M is lower than PTC Therapeutics's net income of $866.6M. Notably, Regenxbio's price-to-earnings ratio is -- while PTC Therapeutics's PE ratio is 7.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.16x versus 2.06x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.83% compared to Regenxbio's net margin of 26.7%. Regenxbio's return on equity of -50.09% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Regenxbio has a consensus price target of $32.00, signalling upside risk potential of 229.56%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $790.88 which suggests that it could grow by 35.5%. Given that Regenxbio has higher upside potential than Regeneron Pharmaceuticals, analysts believe Regenxbio is more attractive than Regeneron Pharmaceuticals.

Regenxbio has a beta of 1.115, which suggesting that the stock is 11.488% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.3% to investors and pays a quarterly dividend of $0.88 per share. Regenxbio pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Regenxbio's net income of $6.1M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Regenxbio's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 14.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.16x versus 4.77x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 6.83% compared to Regenxbio's net margin of -60.08%. Regenxbio's return on equity of -50.09% beat Sarepta Therapeutics's return on equity of -20.94%.

Regenxbio has a consensus price target of $32.00, signalling upside risk potential of 229.56%. On the other hand Sarepta Therapeutics has an analysts' consensus of $89.96 which suggests that it could grow by 137.36%. Given that Regenxbio has higher upside potential than Sarepta Therapeutics, analysts believe Regenxbio is more attractive than Sarepta Therapeutics.

Regenxbio has a beta of 1.115, which suggesting that the stock is 11.488% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.846, suggesting its less volatile than the S&P 500 by 15.365%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Regenxbio's net income of $6.1M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Regenxbio's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.16x versus 1.89x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 6.83% compared to Regenxbio's net margin of 23.33%. Regenxbio's return on equity of -50.09% beat Vertex Pharmaceuticals's return on equity of -6.04%.

Regenxbio has a consensus price target of $32.00, signalling upside risk potential of 229.56%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 14.71%. Given that Regenxbio has higher upside potential than Vertex Pharmaceuticals, analysts believe Regenxbio is more attractive than Vertex Pharmaceuticals.

Regenxbio has a beta of 1.115, which suggesting that the stock is 11.488% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.511, suggesting its less volatile than the S&P 500 by 48.928%.

Regenxbio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Regenxbio pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Regenxbio quarterly revenues are $89M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Regenxbio's net income of $6.1M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Regenxbio's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Regenxbio is 3.16x versus 10.17x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.